ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO112

The Exact Time Difference between PLA2R Antibody and Proteinuria in Reflecting Disease Activity Change in Idiopathic Membranous Nephropathy

Session Information

Category: Glomerular

  • 1004 Clinical/Diagnostic Renal Pathology and Lab Medicine


  • Lin, Weifeng, Peking Universty Third Hospital, Beijing, China
  • Li, Hang, Peking Union Medical college hosiptal, Beijing, China
  • Li, Xuemei, Peking Union Medical College Hospital, Beijing, China
  • Chen, Limeng, Peking Union Medical College Hospital, Beijing, China
  • Li, Xuewang, Peking Union Medical College Hospital, Beijing, China

According to most studies , PLA2R antibody was faster than proteinuria in reflecting disease activity in idiopathic membranous nephropathy. However, the exact time difference is still unknown. This study was to reveal the precise time difference between them, which could guild clinical practice.


A total of 102 patients with IMN proven by kidney biopsy at Peking Union Medical College Hospital from January 1, 2014 to December 31, 2015 were enrolled. An observationally prospective follow-up was conducted monthly to monitor the changes in PLA2R antibody titer and disease activity changes based on proteinuria in IMN. The study end point was clinical remission based on proteinuria or the research deadline.


The average follow-up time was (13.83±3.14) months, with a minimum time of 7 months and a maximum time of 21 months. The overall average time of PLA2R antibody turning negative in clinical remission group based on proteinuria was (3.11±2.97) months. In subgroups,the average time of antibody turning negative in the complete remission (CR) group and partial remission (PR) group were ( 3.17±3.23) months and (3.13±3.05) months, respectively. Importantly, our study showed that PLA2R antibody was (1.91±2.51) months earlier turning negative than proteinuria reaching clinical PR in IMN. Also, there was (6.91±3.33) months earlier for antibody to turn negative than proteinuria to achieve clinical CR. There was (3.09±4.66) months earlier for antibody turning positive again than proteinuria recurrence.


The PLA2R antibody changes was faster than proteinuria in reflecting disease activity changes in IMN,about 2 months ahead of proteinuria PR , about 7months ahead of proteinuria CR and about 3 months ahead of proteinuria recurrence.